<DOC>
	<DOC>NCT00643071</DOC>
	<brief_summary>Patients with severe refractory ulcerative colitis (UC) or those who received placebo in study F506-CL-1107 will receive tacrolimus for a maximum of 12 weeks. Safety and efficacy will be evaluated.</brief_summary>
	<brief_title>Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients</brief_title>
	<detailed_description>Patients with severe refractory ulcerative colitis (UC) or those who received placebo in study F506-CL-1107 study can participate in this study. Patients will receive tacrolimus for a maximum of 12 weeks in an open-label study manner. Improvement of Disease Activity Index (DAI) score and other efficacy scores will be evaluated during the drug administration period.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Severe refractory UC patients who meets the following criteria Disease activity: more than 6 times of stool a day, bloody stool, moderate to severe endoscopic finding Steroid resistant or dependent OR Moderate to severe refractory UC patients who participated and received placebo in F506CL1107 study Mild or fulminant type Renal failure patients, hepatic failure patients Patients taking 6mercaptopurine, cyclosporin or other immunosuppressants within 12 weeks prior to entry Patients who received LCAP or GCAP within 2 weeks prior to entry Patients who changed the dose of steroid or started steroid within 2 weeks prior to entry Patients who changed the dose of steroid or started steroid within 1 week prior to entry in case they received more than 40 mg/ day or 1mg/kg/day of steroid just before the study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>FK506</keyword>
	<keyword>Treatment outcome</keyword>
</DOC>